Breaking News

Merck Assumes Responsibility for Development of MK-8690

Signs agreement with Dr. Falk Pharma GmbH for certain development and commercialization rights to investigational anti-CD30 ligand monoclonal antibody.

Author Image

By: Charlie Sternberg

Associate Editor

Merck, through a subsidiary (Prometheus BioSciences), has reached an agreement with Dr. Falk Pharma GmbH to discontinue an existing contract concerning co-development and co-commercialization rights in certain territories for MK-8690 (formerly PRA-052), and for Merck to assume full responsibility for the development program going forward. MK-8690 is an investigational anti-CD30 ligand monoclonal antibody being evaluated by Merck in an early-stage clinical trial. Under the terms of the agre...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters